Get the Stockscreener App
1.28
36.46%
0.342
Xilio Therapeutics Inc Stock (XLO) Forecast
The Xilio Therapeutics Inc (XLO) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $12.98, representing a +913.86% increase from the current price of $1.28. The highest analyst price target is $12.87, and the lowest is $13.09.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month XLO Price Target
Average 9.5543
(+646.43% Upside)
Is Xilio Therapeutics Inc (XLO) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 65.43 | Neutral |
| STOCH(9,6) | 37.16 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | 0.00643 | Buy |
| ADX(14) | 16.21 | Neutral |
| William %R | 0.00 | Sell |
| CCI(14) | 106.91 | Buy |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.0154
Buy
|
1.0255
Buy
|
| MA20 |
1.0132
Buy
|
1.0195
Buy
|
| MA50 |
1.0118
Buy
|
0.9945
Buy
|
| MA100 |
0.9169
Buy
|
0.9714
Buy
|
| MA200 |
0.9706
Buy
|
1.0438
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, XLO could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 2 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on XLO, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 65.43 indicates that XLO is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 37.16 indicates that XLO is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that XLO is oversold. This suggests that XLO price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 16.21 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 106.91 indicates that XLO is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term XLO price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Xilio Therapeutics Inc financial reports and earnings history, Xilio Therapeutics Inc (XLO) stock could reach $1.7909 by 2030, $67.69 by 2040 and $21.15 by 2050. See the projected annual prices until 2050 of the Xilio Therapeutics Inc stock below:
- Xilio Therapeutics Inc (XLO) is expected to reach an average price of $22.06 in 2035, with a high prediction of $23.90 and a low estimate of $22.12. This indicates an $1,624% rise from the last recorded price of $1.28.
- Xilio Therapeutics Inc (XLO) stock is projected to chart a bullish course in 2040, with an average price target of $65.34, representing an $5,005% surge from its current level. The forecast ranges from a conservative $65.56 to a sky-high $67.69.
- Our analysts predict Xilio Therapeutics Inc (XLO) to jump 9,869% by 2045, soaring from $128.17 to an average price of $127.61, potentially reaching $128.70. While $128.17 is the low estimate, the potential upside is significant.
- Xilio Therapeutics Inc (XLO) stock is expected to climb by 2050, reaching an average of $17.81, a $1,291% jump from its current level. However, a wide range of estimates exists, with high and low targets of $21.15 and $17.87, respectively, highlighting the market's uncertainty.
Xilio Therapeutics Inc Stock (XLO) Year by Year Forecast
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2025
Xilio Therapeutics Inc Stock (XLO) is expected to reach an average price of $9.5543 in 2025, with a high prediction of $12.87 and a low estimate of $6.2392. This indicates an +646.43% rise from the last recorded price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $13.08 | $13.09 | $12.87 | +921.83% |
| February, 2025 | $11.90 | $12.21 | $12.42 | +829.97% |
| March, 2025 | $11.98 | $11.90 | $11.48 | +835.76% |
| April, 2025 | $11.04 | $11.70 | $11.65 | +762.73% |
| May, 2025 | $10.54 | $10.69 | $10.39 | +723.21% |
| June, 2025 | $10.42 | $10.43 | $10.40 | +714.16% |
| July, 2025 | $9.6964 | $9.7354 | $10.23 | +657.53% |
| August, 2025 | $9.2505 | $9.4995 | $9.2505 | +622.70% |
| September, 2025 | $8.2947 | $8.5747 | $8.7716 | +548.02% |
| October, 2025 | $6.8599 | $7.1978 | $6.8599 | +435.93% |
| November, 2025 | $7.144 | $6.7419 | $6.7127 | +458.13% |
| December, 2025 | $5.9792 | $6.2392 | $6.7751 | +367.13% |
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2026
The predicted value for Xilio Therapeutics Inc (XLO) in 2026 is set at an average of $3.9617. Estimates vary from a peak of $5.9003 to a trough of $2.0232, indicating an +209.51% surge from the present price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $5.5934 | $5.7434 | $5.9003 | +336.98% |
| February, 2026 | $5.2675 | $5.3365 | $5.3844 | +311.53% |
| March, 2026 | $5.1117 | $5.2017 | $4.9896 | +299.35% |
| April, 2026 | $4.2269 | $4.3119 | $4.8127 | +230.22% |
| May, 2026 | $3.821 | $3.991 | $4.0579 | +198.52% |
| June, 2026 | $3.6952 | $3.4781 | $3.542 | +188.68% |
| July, 2026 | $3.4703 | $3.6872 | $3.4583 | +171.12% |
| August, 2026 | $3.4645 | $3.0435 | $3.1688 | +170.66% |
| September, 2026 | $3.4023 | $3.4023 | $3.3576 | +165.80% |
| October, 2026 | $2.8738 | $3.1838 | $3.2418 | +124.52% |
| November, 2026 | $2.568 | $2.599 | $2.7059 | +100.62% |
| December, 2026 | $1.8642 | $2.0232 | $2.3919 | +45.64% |
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Xilio Therapeutics Inc (XLO) is $14.53, with a high forecast of $28.92 and a low forecast of $0.1446. This indicates an +1,035% increase from the last price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.3498 | $1.4159 | $1.5942 | +5.45% |
| February, 2027 | $0.3915 | $0.4215 | $0.1694 | -69.42% |
| March, 2027 | $18.32 | $0.1446 | $16.88 | +1,331% |
| April, 2027 | $26.52 | $19.02 | $22.55 | +1,972% |
| May, 2027 | $22.42 | $23.73 | $26.95 | +1,651% |
| June, 2027 | $23.52 | $24.37 | $23.36 | +1,737% |
| July, 2027 | $22.95 | $24.74 | $22.89 | +1,693% |
| August, 2027 | $27.38 | $24.17 | $26.75 | +2,039% |
| September, 2027 | $27.74 | $27.48 | $26.50 | +2,067% |
| October, 2027 | $29.37 | $29.51 | $28.92 | +2,195% |
| November, 2027 | $28.93 | $29.07 | $28.76 | +2,160% |
| December, 2027 | $27.54 | $27.90 | $28.34 | +2,052% |
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2028
In 2028, Xilio Therapeutics Inc (XLO) is projected to reach an average price of $20.21, with a high projection of $26.46 and a low estimate of $13.96. This indicates an +1,479% rise from the last price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $26.49 | $26.69 | $26.46 | +1,970% |
| February, 2028 | $26.11 | $26.17 | $25.86 | +1,940% |
| March, 2028 | $24.07 | $24.23 | $25.70 | +1,780% |
| April, 2028 | $23.86 | $23.93 | $23.76 | +1,764% |
| May, 2028 | $22.16 | $22.41 | $23.25 | +1,631% |
| June, 2028 | $21.42 | $21.61 | $21.57 | +1,573% |
| July, 2028 | $19.97 | $20.19 | $20.85 | +1,460% |
| August, 2028 | $17.78 | $17.90 | $19.37 | +1,289% |
| September, 2028 | $16.75 | $16.92 | $17.37 | +1,209% |
| October, 2028 | $16.25 | $16.56 | $16.64 | +1,170% |
| November, 2028 | $14.74 | $15.09 | $15.83 | +1,052% |
| December, 2028 | $13.95 | $13.96 | $14.48 | +989.91% |
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2029
The 2029 price forecast for Xilio Therapeutics Inc Stock (XLO) is $8.0009 on average, with a high prediction of $13.51 and a low estimate of $2.4888. This represents an +525.07% increase from the previous price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $12.98 | $13.17 | $13.51 | +914.16% |
| February, 2029 | $11.84 | $12.10 | $12.56 | +824.97% |
| March, 2029 | $10.86 | $10.97 | $11.50 | +748.27% |
| April, 2029 | $9.7262 | $9.7912 | $10.50 | +659.86% |
| May, 2029 | $9.286 | $9.4845 | $9.4682 | +625.47% |
| June, 2029 | $8.1148 | $8.3198 | $8.7457 | +533.97% |
| July, 2029 | $8.0881 | $8.0669 | $7.9031 | +531.89% |
| August, 2029 | $7.4515 | $7.4935 | $7.8652 | +482.15% |
| September, 2029 | $6.2729 | $6.3257 | $7.0556 | +390.07% |
| October, 2029 | $5.0512 | $5.1621 | $5.9868 | +294.62% |
| November, 2029 | $3.8005 | $3.9347 | $4.7843 | +196.91% |
| December, 2029 | $2.3988 | $2.4888 | $3.5239 | +87.41% |
Xilio Therapeutics Inc Stock (XLO) Price Forecast for 2030
Xilio Therapeutics Inc Stock (XLO) is expected to reach an average price of $23.86 in 2030, with a high forecast of $46.42 and a low forecast of $1.2992. This signifies an +1,764% surge from the last price of $1.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.545 | $1.2992 | $1.7909 | +20.70% |
| February, 2030 | $40.04 | $39.14 | $37.25 | +3,028% |
| March, 2030 | $47.80 | $44.88 | $46.42 | +3,635% |
| April, 2030 | $42.33 | $42.94 | $41.34 | +3,207% |
| May, 2030 | $41.59 | $43.06 | $41.92 | +3,149% |
| June, 2030 | $44.79 | $42.09 | $41.08 | +3,399% |
| July, 2030 | $44.58 | $44.94 | $44.28 | +3,383% |
| August, 2030 | $46.36 | $44.50 | $45.55 | +3,522% |
| September, 2030 | $45.10 | $46.04 | $45.13 | +3,424% |
| October, 2030 | $44.02 | $44.27 | $44.63 | +3,339% |
| November, 2030 | $41.81 | $42.12 | $43.10 | +3,166% |
| December, 2030 | $40.85 | $40.99 | $40.87 | +3,092% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):